Blue Shield Participation

Similar documents
Measure Up Pressure Down. Scott Flinn MD Fritz Steen RN

Implementation of JNC- 8 Hypertension Recommendations: Combining evidence and value-based practice strategies for accountable care

Best Practices in Cardiac Care: Getting with the Guidelines

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

ASSESS AND ADDRESS RISK OF CARDIOVASCULAR DISEASE

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.

Preventing and Treating High Blood Pressure

Monthly Campaign Webinar. May 19, 2016

Preventing 1 Million Heart Attacks and Strokes by 2022

Hypertension Update Clinical Controversies Regarding Age and Race

Crossing The Quality Chasm: Cardiovascular Care

Hypertension (JNC-8)

PHASE Preventing Heart Attacks & Strokes Everyday

Advances in Alignment, Measurement, and Performance MY 2017 Results Highlights

Hypertension Update 2014:

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

Modern Management of Hypertension

What in the World is Functional Medicine?

Modern Management of Hypertension: Where Do We Draw the Line?

Hypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute

Objectives. Heart failure and Hypertension. Definition & epidemiology of heart failure HEART FAILURE 3/12/2016. Kirsten Bibbins-Domingo, PhD, MD, MAS

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

CMMI Project: San Diego A Heart Attack and Stroke Free Zone. Parag Agnihotri, MD Chair of the Healthcare Committee

Measure Up/Pressure Down Medical Group Success

REDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT

Engaging patients and providers with the right information, at the right time, to do the right thing

Variation in Care Improvement Opportunities Suggests Need for Tailored Clinician-Specific Improvement Interventions

ACE. Inhibitors. Quiz feedback

Managing Hypertension in 2016

Treating Hypertension in 2018: What Makes the Most Sense Today?

Right Care Initiative Michael H. Kanter, MD Medical Director of Quality & Clinical Analysis Southern California Permanente Medical Group

ADVANCES IN MANAGEMENT OF HYPERTENSION

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

C2/D2: Diabetes Care at Kaiser Permanente Population-based Approach

Hypertension Pharmacotherapy: A Practical Approach

Target: BP Overview with Lake Superior QIN Wednesday, February 22, :00 PM 1:00 PM CST

ADVANCES IN MANAGEMENT OF HYPERTENSION

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Driving Outcomes By Scaling Population Health Management

Physician/Clinic Collaborative Practice Agreement

Adult Blood Pressure Clinician Guide June 2018

Update in Hypertension

Cardio-Protective Medication Bundle. Louis H. Carter II, PharmD.

Treating Hypertension in Individuals with Diabetes

Best Practices in Managing Patients with Heart Failure Collaborative

Value Based Pay for Performance Results & Highlights Measurement Year September 2017

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

2015 Healthy Heart. Program Evaluation. Our mission is to improve the health and quality of life of our members

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

Update in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP

Blood Pressure Management: A Journey in Quality Improvement Phil E. Yphantides, M.D.

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA

Hypertension and Cardiovascular Disease

Advanced Strategies and Measurement. Foresight Family Physicians Primary Care Partners The Telluride Medical Center

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

Heart Failure Clinician Guide JANUARY 2018

Essentia Health Duluth Clinic RN Hypertension Management Pilot

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI

Managing Chronic Kidney Disease: Reducing Risk for CKD Progression

Cost-Effective Process to Improve Drug Adherence for Medicare 5-Star

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?

Diabetes Complications Guideline Based Screening, Management, and Referral

Hypertension: 2016 Clinical Update

[PDF] CAN DRINKING WATER LOWER YOUR BLOOD PRESSURE

Hypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016

DEPARTMENT OF GENERAL MEDICINE WELCOMES

CVD Prevention Optimal Value Pathway

Objectives. Describe results and implications of recent landmark hypertension trials

Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension

ALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status

Population Health Management Design: Optimizing the Outcomes for Special Populations 21th Annual ASHP Conference for Pharmacy Leaders

ALLHAT Investigators Report 10-Year Follow-up and Stand by Diuretics as First-Step Antihypertensive Treatment

Hypertension Controversies: SPRINTing to New Goals

Update on Current Trends in Hypertension Management

CKD & HT. Anne-Marie Angus

What Does Walt Disney Have To Do With Heath Care: The Importance of Quality, Reliability, and Engaged Physicians

APPENDIX D: PHARMACOTYHERAPY EVIDENCE

Patients Will Be Safe With A-L-L Heart Protection. Care Management Institute Kaiser Permanente 9/2012

Management of High Blood Pressure in Adults

16 th Annual IHA Stakeholders Meeting Session 2C

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Heart Failure Clinician Guide JANUARY 2016

2012 Diabetes. Program Evaluation. Our mission is to improve the health and quality of life of our members

Network Hypertension Algorithm

Chronic Disease Management when Resources are Limited

Diabetic medications

Creating Policy to Promote and Support Individual Change. Ann Albright, PhD, RD

Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm

American Society for Automation in Pharmacy January 25, 2013

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

This product was developed by the Help Yourself: Chronic Disease Self Management Program at Marshall University School of Medicine in Huntington, WV

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

The State of Hypertension in NZ in 2010 personal view

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Transcription:

9 th Annual Right Care Initiative Summit Blue Shield Participation Scott Flinn, MD Regional Medical Director Blue Shield of California 1

Care Worthy of our Family and Friends 2

Bottom Line Up Front Blue Shield of California has historically been in the middle of the pack on the RCI metrics DMHC recently required Blue Shield to develop a plan to improve its performance with a goal of achieving the 90 th percentile in RCI metrics by 2018 Blue Shield of California has developed that plan and has begun the process of implementation; this presentation is a review of progress to date 2016 Ultimately, the goal is the elimination of preventable strokes and heart attacks for all Californians 3

Where we have been RCI metrics 2014 Percentile 4

Where we are now Developed a plan which includes engaging partner Provider Organizations with enough membership to allow us to reach 90 th percentile. Currently 6 organizations agreeing to participate - 80,000 members Developed Best Practices assessment for Diabetes and Hypertension care based on RCI and other work Conducting gap analysis with partner POs using Best Practices assessment tool, and development of plan of action based on the gap analysis 5

Where we are now Expanding Pharmacy programs Implementing quality goals in ACO contracts Attending University of Best Practices in all 3 locations 6

Best Practices Include: Engaging Providers and Patients Adopting and Implementing a treatment algorithm Intensifying treatment rapidly Implementing a care team which includes a pharmacist and Certified Diabetic Educator Continuously measuring success - registry Publicly reporting inside the Provider Organization 7

Decrease Deaths over 17% (1 in 6) in 2 years Treat them NOW 8

What have we learned so far Many provider organizations have efforts towards RCI goals at various levels RCI synergizes with other programs e.g. CDC/CMS Million Hearts, AMGF Measure Up Pressure Down and Together2Goal, AHA Target BP, Know Your Numbers Participation in RCI gives a framework for the effort Hypertension control has the biggest near term effects 9

Where do We Want to Go Continue to enlist Provider Organizations in effort Continue to refine approach based on experience with partner Provider Organizations and through participating in UBP and other venues Reach 90 th percentile in RCI Metrics Eliminate preventable strokes and heart attacks 10

Care Worthy of our Family and Friends 11

What is the intervention that has the greatest near term impact on reducing strokes and heart attacks? A. Lipid Management B. Diabetes Management C. Hypertension Management D. Medication Reconciliation 25% 25% 25% 25% A B C D 12 12

What has been shown as the best ways to motivate providers to improve performance? A. Cash B. Public reporting comparing providers to peers C. Medical Director conversations D. Point of Care reminders in the HER 25% 25% 25% 25% A B C D 13 13

Discussion 14

Appendix 15

Based on the Be There San Diego Simplified Hypertension Treatment Approach ACE-Inhibitor* / Thiazide Diuretic Lisinopril / HCTZ (Advance as needed) 20 / 25 mg X ½ daily 20 / 25 mg X 1 daily 20 / 25 mg X 2 daily Pregnancy Potential: Avoid ACE-Inhibitors * If not in control Calcium Channel Blocker Add amlodipine 5 mg X ½ daily 5 mg X 1 daily 10 mg daily If not in control Beta-Blocker OR Spironolactone Add metoprolol succinate ER 25 mg daily 50 mg daily 100 mg daily (Keep heart rate > 55) OR IF on thiazide AND egfr 60 ml/min AND K < 4.5 Add spironolactone 12.5 mg daily 25 mg daily For those with high cardiovascular risk consider adding a statin according to guidelines which can result in an additional 25% reduction 16 in cardiovascular events. Reference: The Lancet, Volume 376, Issue 9753, Pages 1670-1681,

Pharmacist on the care team Report on HTN medication prescriptions surrogate for HN control Medication Therapy Management using Collaborative Practice Agreements, intensification of therapy per protocol while keeping Primary Care Physician informed Medication Adherence and patient outreach 17

AMGF Together2 Goal program Program to address diabetes care http://together2goal.org/assets/pdf/toolkit/gettingstarted.pdf Four essential planks Adopt an algorithm Measuring A1C every 3-6months Rapid intensification of treatment every 30 days Evaluate CVD risk and treat Quick wins If DM and no A1C get them in A1C >9 and no visit in 6 months get them in A1C > 6.5 and no Dx of DM get them in 18

From ADA published 2015 19

DM and CVD risk Diabetic patients - Measure their CVD risk ALL treatment Aspirin Lisinopril Lipitor 20

Reporting and Rewarding - Registry Provides actionable data for identifying clinical opportunities Provides means of tracking progress, and providing feedback, and reporting and recognizing 21

Tools http://www.uspreventiveservicestaskforce.org/page/document/updat esummaryfinal/aspirin-to-prevent-cardiovascular-disease-andcancer?ds=1&s=aspirin http://www.capg.org/modules/showdocument.aspx?documentid=44 http://clincalc.com/cardiology/ascvd/pooledcohort.aspx http://together2goal.org/assets/pdf/toolkit/adopttreatmentalgorithm. pdf 22